Shenguan Holdings (Group) Limited

Shenguan Holdings (Group) Limited

0829.HK
Shenguan Holdings (Group) LimitedHK flagHong Kong Stock Exchange
0.16
HKD
+0.00
- -
510.42MMarket Cap
Shenguan Holdings (Group) Limited
0829.HK
(Hong Kong Stock Exchange)

Recent

price

0.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.22
0.45
0.5
0.5
0.42
0.32
0.3
0.31
0.28
0.31
0.3
0.36
0.32
0.34
0.31
0.32
Revenue per Share
0.1
0.21
0.23
0.23
0.16
0.09
0.05
0.02
0.02
0.02
0.03
0.04
0.01
0.01
0.01
-0.02
Basic EPS, GAAP
0.02
0.14
0.12
0.08
0.07
0.06
0.05
0.12
0.08
0.09
0.11
0.02
0.01
0.03
-0.07
-0.04
Free Cash Flow per Basic Share
0.03
0.08
0.09
0.14
0.15
0.03
0.03
0.03
0.03
0.03
0.05
0.05
0.05
0.06
0.04
0.04
Dividend per Share
0.09
0.26
0.38
0.45
0.6
0.69
0.75
0.77
0.79
0.01
0.79
0.78
0.74
0.69
0.66
0.61
Book Value per Share
0.35
0.54
0.67
0.76
0.76
0.75
0.79
0.79
0.8
0.85
0.8
0.82
0.78
0.74
0.71
0.66
Tangible Book Value per Share
5,252
3,322
3,323
3,324
3,319
3,283
3,259
3,259
3,254
3,231
3,230
3,230
3,230
3,230
3,230
3,230
Basic Weighted Avg Shares
1,153
1,502
1,648
1,654
1,403
1,055
981
1,008
899
998
962
1,168
1,032
1,110
1,017
1,023
Sales/Revenue/Turnover
56.26
54.33
54.36
53.96
48.34
33.71
12.37
5.09
14.06
3.83
7.61
11.8
-1.79
-0.39
2.28
-4.77
Operating Margin (%)
34
46
55
75
93
115
150
152
149
150
139
100
101
101
84
77
Depreciation Expense
513
689
748
771
547
291
154
69
80
75
91
123
24
31
27
-70
Net Income, GAAP
20.23
18.83
19.57
17.41
19.03
15.29
13.89
13.72
25.92
20.59
19.98
26.37
39.83
56.5
34.54
- -
Effective Tax Rate (%)
44.54
45.89
45.39
46.62
39.02
27.63
15.72
6.82
8.93
7.56
9.44
10.5
2.28
2.81
2.62
-6.82
Profit Margin (%)
1,162
852
888
1,005
1,057
1,150
1,202
1,257
1,254
1,218
1,102
1,111
1,164
1,076
1,031
994
Working Capital
140
20
60
- -
- -
- -
- -
- -
- -
- -
2
6
2
1
4
3
LT Debt
1,865
1,905
2,345
2,644
2,636
2,870
2,895
2,848
2,814
2,776
2,689
2,656
2,519
2,376
2,293
2,126
Total Equity
28.37
32.97
31.55
27.09
17.47
8.78
3.13
1.41
3.14
1.05
2.04
3.4
-0.36
-0.07
0.58
- -
Return on Invested Capital (%)
137.19
84.94
62.08
49.1
25.17
11.05
6.61
3.27
3.42
6.13
6.82
4.56
1.06
1.36
1.19
- -
Return on Capital (%)
200.62
101.07
70.25
56.16
31.46
13.64
6.56
2.79
3.17
5.8
7.01
4.82
0.96
1.35
1.22
-3.4
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.93%
-4.56%
-7.26%
Free Cash Flow
-20.36%
-66.36%
-47.48%
Net Income, GAAP
-46.09%
-77.88%
-361.67%
Sales/Revenue/Turnover
0.19%
1.92%
0.64%
Total Cash Common Dividend
3.97%
-6.37%
0.75%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,110
2024
- -
- -
- -
- -
1,017
2025
- -
- -
- -
- -
1,023

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.06
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.04
Business
Shenguan Holdings (Group) Limited, an investment holding company incorporated in the Cayman Islands in 1989 and headquartered in Causeway Bay, Hong Kong, principally manufactures and sells collagen-based products worldwide under the Shenguan brand. The Group produces edible collagen sausage casings, including its six high-end series of fried, crispy, fresh, tender, bright and colorful variants that account for about 40% of first-half 2025 sales; collagen food products such as Beef Tendon and Bo Bo Chicken; collagen skincare products; polymer collagen medical biomaterials featuring low endotoxin levels below FDA standards; pharmaceutical products and intermediates; collagen medical devices including dental sponges and bone filling materials advancing through clinical trials and regulatory approvals; fine chemicals for human use; and maternal-infant products. Operations span Mainland China, where over 90% of revenue and non-current assets concentrate primarily in Guangxi; Asia excluding Mainland China; and other regions including Southeast Asia, Europe, South America and the United States, serving leading meat processors with certifications like ISO9001, ISO22000, Halal and US FDA export registration. In recent developments, the Group reported 2025 interim results on 25 August 2025 showing revenue of RMB444 million and a net loss of RMB41 million attributable to owners amid weak consumer demand and higher inventory provisions, while achieving 93% sales growth in non-sausage casing segments particularly polymer collagen medical biomaterials; it intensified intelligent production upgrades, raw material supply diversification and market expansion for new collagen applications; advanced clinical trials for dental collagen sponges and refined approvals for collagen bone filling biomaterials; enhanced production efficiency through equipment standardization and cost controls; earned honors including China's 500 Most Valuable Brands 2025 and retained Guangxi collagen research center status; and accumulated 116 patents with collaborations like Huazhong University of Science and Technology yielding publications and joint innovations. Shenguan Holdings is a subsidiary of Rich Top Future Limited and employs about 3,010 staff focused on high-quality collagen technology originating from China's first edible casing patent over 40 years ago.